STAT

‘I needed to be next to my patient’: The cancer doctor who braved Harvey to reach his hospital

Dr. Adi Diab walked roughly three miles, wading through stretches shin-deep waters, to help his team conduct an experimental treatment.
A Houston neighborhood flooded by rain from Harvey.

Timing was everything for this cancer patient. Scientists had already harvested billions of cells in a cutting-edge lab for months. The doctors had performed a handful of rounds of chemotherapy to weaken the tumor. Now came the most crucial part: infusing those cultivated cells back into the patient. If the experimental treatment worked, Dr. Adi Diab felt the patient might have a shot at beating late-stage melanoma.

The Houston oncologist had his patient travel over 100 miles from Louisiana to be admitted at in advance of the infusion. In the midst of chemotherapy, the storm that would become Harvey slowly spun west through

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks